We love to hear from our listeners. Send us a message. For episode 131 of Cell &amp; Gene: The Podcast, we’re sharing a recent &quot;Better Biopharma&quot; roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues. Hosted by Tyler Menichiello, this conversation brings together chief editors from across the Life Science Connect network to take a midyear look at what’s shaping the pharmaceutical and biotech landscape in 2026. Featuring perspectives from Katie Anderson, Jeff Buguliskis, Ben Comer, Ray Dogum, Rachel Grabenhofer, Dan Schell, Anna Rose Welch, and Harris, this is a valuable listen for anyone looking to better understand where the industry is headed, and how CGT fits into that broader trajectory. https://www.bioprocessonline.com/solution/better-biopharma Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell &amp; Gene Connect with me on LinkedIn

Cell & Gene: The Podcast Presents: Better Biopharma’s Editors’ Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Cell & Gene: The Podcast

# Full Transcript

**Podcast:** Cell &amp; Gene: The Podcast

## Participants

- **Erin Harris** (Cell & Gene: The Podcast)
- **Tyler Minichello** (Better Biopharma)
- **Katie Anderson** (Pharmaceutical Online)
- **Jeff Bogaliskis** (Outsourced Pharma)
- **Ben Comer** (Life Science Leader)
- **Ray Dogum** (Drug Discovery Online)
- **Rachel Grabenhofer** (Clinical Supply Leader)
- **Dan Schell** (Clinical Leader)
- **Anna Rose Welch** (Advancing RNA)
- **Erin Harris** (Cell & Gene: The Podcast)

## Transcript

Hi everyone and welcome to episode 131 of Cell & Gene: The Podcast. I'm your host Erin Harris. What you're about to hear is an episode of Better Biopharma. It's a podcast hosted by my colleague, Tyler Minichello, who I want to sincerely thank for the opportunity to share this conversation with all of you. I'd also strongly recommend adding Better Biopharma to your regular rotation if you're not already subscribed. Tyler brought together me and my Life Science Connect editorial

colleagues for an important discussion and the group's collective expertise, which by the way spans decades across the Life Sciences industry, is exactly what makes this conversation so valuable for those of us in Cell & Gene Therapy. We dig into the forces shaping 2026 and we talk about AI's expanding role in manufacturing and clinical operations. We talk about shifting supply chain strategies. We talk involving regulatory approaches.

and the broader investment climate and the broader investment and the broader investment climate. Just as importantly, this conversation reflects the reality that Cell & Gene Therapy doesn't operate in a vacuum. It captures both the depth within advanced therapies and the broader life sciences landscape that will ultimately determine how and how fast these conversations and innovations reach patients. It's a timely and a candid check-in on where the industry stands today and where it's

still needs to go. This roundtable. This roundtable features Katie Anderson, Chief Editor at Pharmaceutical Online, Jeff Bogaliskus, PhD, Deputy Chief Editor at Outsourced Pharma, Ben Comer, Chief Editor at Life Science Leader and host of the Business of Biotech Podcast, Ray Dogam, Chief Editor at Drug Discovery Online, Rachel Grabenhoffer, Chief Editor at Clinical Supply Leader, Dan Schell, Chief Editor at Clinical Leader, and Anna Rose Wells, Chief Editor at Clinical Leader, and Anna Rose Wells, Chief Editor at Clinical Leader, and Anna Rose Wells, Chief Editor at Clinical Leader.

And Anna Rose, Chief Editor at Advanced Science Leader, and Anna Rose, and Anna Rose, and Anna Rose, Chief Editor at Advancing RNA, and me. Here's the deal. If you're looking for a clear cross-industry perspective on where biopharma is headed and actually what that means for cell gene therapy, this is a conversation you will definitely want to tune into. And so without further ado, here is the editor's roundtable amid your look at the 2026 life sciences industry from Better...

Cell & Gene: The Podcast Presents: Better Biopharma’s Editors’ Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

Cell & Gene: The Podcast Presents: Better Biopharma’s Editors’ Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.